Chong Kun Dang Receives Global Phase 3 Approval for COVID-19 Treatment 'Napabeltan'

[Asia Economy Reporter Cho Hyun-ui] Chong Kun Dang's blood anticoagulant and acute pancreatitis treatment drug 'Napabeltan' has received approval for a Phase 3 clinical trial plan for the treatment of the novel coronavirus infection (COVID-19) in Australia.

On the 14th, Chong Kun Dang announced, "Napabeltan has received approval from the Australian Therapeutic Goods Administration for a Phase 3 clinical trial plan to participate in the global clinical project 'ASCOT' (Australasian COVID-19 Trial) being conducted to end COVID-19."

The ASCOT trial is led by the Peter Doherty Institute, an infectious disease research institute at the University of Melbourne, Australia, with over 70 institutions participating across Australia, New Zealand, and India.

Accordingly, Chong Kun Dang will conduct clinical trials for the development of Napabeltan as a COVID-19 treatment involving 2,440 COVID-19 patients in Australia, New Zealand, and India. Previously, Chong Kun Dang had received clinical trial approvals for Napabeltan in four countries: Korea, Russia, Mexico, and Senegal.

Chong Kun Dang stated, "By expanding Napabeltan's clinical trials from four to seven countries, we aim to verify the drug's efficacy across diverse ethnic groups and rapidly secure clinical results necessary for global approval."

This content was produced with the assistance of AI translation services.